Drug Trial Radar · NCT05367960
An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome
Last checked: Nov 19, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
314
Actual
Start
Nov 1, 2022
Primary completion
Sep 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Tetra Discovery PartnersIndustry
- Sponsor type
- Industry
- First posted
- May 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 9 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 4-year, open-label extension (OLE) study for subjects completing one of two double-blind clinical trials with BPN14770, Study BPN14770-CNS-301 (in adult males) and Study BPN14770-CNS-204 (in adolescent males).
Conditions
- Fragile X Syndrome
Interventions
Zatolmilast/ BPN14770Drug
25mg zatolmilast/BPN14770 (Adults) or 15 mg zatolmilast/BPN14770 (Adolescents \<43 kg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of BPN14770Time frame: 24 months
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Amnova Clinical Research
Irvine, California
Thompson Autism & Neurodevelopment Center - CHOC
Orange, California
MIND Institute UC Davis Medical Center
Sacramento, California
Children's Hospital Colorado
Aurora, Colorado
University of Miami
Miami, Florida
Emory University School of Medicine
Atlanta, Georgia
Rush University Medical Center
Chicago, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Kennedy Krieger Institute
Baltimore, Maryland
Boston Children's Hospital
Boston, Massachusetts
U Mass
Worcester, Massachusetts
Icahn School of Medicine at Mount Sinai
New York, New York
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Suburban Research Associates
Media, Pennsylvania
Clinic for Special Children
Strasburg, Pennsylvania
Greenwood Genetic Center
Greenville, South Carolina
University of Utah and Primary Children's Hospital
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.